Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Interventional cardiology

Treating nonischaemic stable CAD lesions—safe to DEFER?

Nature Reviews Cardiology volume 13, pages 7–8 (2016)Cite this article

Subjects

Coronary revascularization has a prominent role in the management of chronic, stable coronary artery disease, but decision-making guided by angiography alone for identifying haemodynamically relevant lesions can be challenging. The DEFER study now demonstrates favourable 15-year outcomes after deferral of revascularization in angiographically relevant, but functionally nonsignificant, coronary lesions.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Summary of the findings from three randomized trials to evaluate FFR for decision-making and PCI guidance in patients with chronic, stable CAD.

References

  1. Topol, E. J. & Nissen, S. E. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92, 2333–2342 (1995).

    Article  CAS  Google Scholar 

  2. Windecker, S. et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 35, 2541–2619 (2014).

    Article  Google Scholar 

  3. Zimmermann, F. M. et al. Deferral versus performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv452.

  4. Pijls, N. H. et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J. Am. Coll. Cardiol. 49, 2105–2111 (2007).

    Article  Google Scholar 

  5. Windecker, S. et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 348, g3859 (2014).

    Article  Google Scholar 

  6. Tonino, P. A. et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360, 213–224 (2009).

    Article  CAS  Google Scholar 

  7. De Bruyne, B. et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N. Engl. J. Med. 367, 991–1001 (2012).

    Article  CAS  Google Scholar 

  8. Gould, K. L. et al. Anatomic versus physiologic assessment of coronary artery disease: role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J. Am. Coll. Cardiol. 62, 1639–1653 (2013).

    Article  Google Scholar 

  9. Stone, G. W. et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364, 226–235 (2011).

    Article  CAS  Google Scholar 

  10. Boden, W. E. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503–1516 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Bern University Hospital, Freiburgstrasse 4 Bern, CH, 3010, Switzerland

    Konstantinos C. Koskinas

  2. Department of Cardiology, Bern University Hospital, Freiburgstrasse 4 Bern, CH, 3010, Switzerland

    Stephan Windecker

Authors
  1. Konstantinos C. Koskinas
    View author publications

    Search author on:PubMed Google Scholar

  2. Stephan Windecker
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Stephan Windecker.

Ethics declarations

Competing interests

S.W. declares that he has received institutional research grants from Abbott, Biotronik, Boston Scientific, Edwards, Medtronic, and St. Jude Medical, and that he has received speaker fees from Abbott, Astra Zeneca, Bayer, Biosensors, Biotronik, Boston Scientific, Edwards, and Medtronic. K.C.K. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koskinas, K., Windecker, S. Treating nonischaemic stable CAD lesions—safe to DEFER?. Nat Rev Cardiol 13, 7–8 (2016). https://doi.org/10.1038/nrcardio.2015.173

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2015.173

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing